Biogen

News

Leqembi maintenance dose filed in US, but SC form delayed

Eisai has filed to extend the label for its Alzheimer’s disease therapy Leqembi to include a maintenance dosing regimen that would reduce the number of intravenous infusio

Market Access

Aduhelm and an expensive failure to launch

Biogen’s treatment for Alzheimer’s was initially regarded as a major treatment breakthrough.

News

Eisai and Biogen facing delay to Leqembi in Europe

Around 14 months after Eisai and Biogen’s Leqembi was filed for approval in the EU, the bloc’s regulatory authority has delayed making a decision on the Alzheimer’s drug.

News

Eisai backs Leqembi’s Japan rollout with insurance policy

A partnership between Eisai and Lifenet that aims to improve insurance cover for people with early dementia has generated its first policy, part of an effort by the pharma

News

Lilly’s Alzheimer’s drug delayed as FDA seeks adcomm

The FDA has said it will seek the advice of independent advisors before it concludes its review of Eli Lilly’s amyloid-targeting Alzheimer’s disease therapy donanemab, del

News

CHMP backs AZ’s danicopan for anaemia in patients with PNH

AstraZeneca has moved a step closer to EU approval of oral Factor D inhibitor danicopan in the EU, after the EMA’s human medicines committee, the CHMP, backed the drug as

Leqembi maintenance dose filed in US, but SC form delayed

Aduhelm and an expensive failure to launch

Eisai and Biogen facing delay to Leqembi in Europe

Eisai backs Leqembi’s Japan rollout with insurance policy

Lilly’s Alzheimer’s drug delayed as FDA seeks adcomm

CHMP backs AZ’s danicopan for anaemia in patients with PNH

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

Biogen

Editor's Picks